Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.49
OREX's Cash-to-Debt is ranked lower than
70% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. OREX: 0.49 )
Ranked among companies with meaningful Cash-to-Debt only.
OREX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.38  Med: 11.59 Max: No Debt
Current: 0.49
Equity-to-Asset -0.03
OREX's Equity-to-Asset is ranked lower than
93% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OREX: -0.03 )
Ranked among companies with meaningful Equity-to-Asset only.
OREX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.15  Med: 0.34 Max: 0.86
Current: -0.03
-3.15
0.86
Piotroski F-Score: 3
Altman Z-Score: -4.26
Beneish M-Score: -0.81
WACC vs ROIC
9.78%
-74.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -182.97
OREX's Operating Margin % is ranked lower than
89% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. OREX: -182.97 )
Ranked among companies with meaningful Operating Margin % only.
OREX' s Operating Margin % Range Over the Past 10 Years
Min: -107754.55  Med: -2442.2 Max: -54.99
Current: -182.97
-107754.55
-54.99
Net Margin % -149.02
OREX's Net Margin % is ranked lower than
85% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. OREX: -149.02 )
Ranked among companies with meaningful Net Margin % only.
OREX' s Net Margin % Range Over the Past 10 Years
Min: -105954.55  Med: -2446.98 Max: -67.59
Current: -149.02
-105954.55
-67.59
ROE % -288.56
OREX's ROE % is ranked lower than
90% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. OREX: -288.56 )
Ranked among companies with meaningful ROE % only.
OREX' s ROE % Range Over the Past 10 Years
Min: -288.56  Med: -109.88 Max: -42.04
Current: -288.56
-288.56
-42.04
ROA % -22.03
OREX's ROA % is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. OREX: -22.03 )
Ranked among companies with meaningful ROA % only.
OREX' s ROA % Range Over the Past 10 Years
Min: -101.77  Med: -51.13 Max: -9.07
Current: -22.03
-101.77
-9.07
ROC (Joel Greenblatt) % -68.26
OREX's ROC (Joel Greenblatt) % is ranked lower than
76% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. OREX: -68.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -34518.01  Med: -5107.71 Max: -57.6
Current: -68.26
-34518.01
-57.6
3-Year Revenue Growth Rate 86.80
OREX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. OREX: 86.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OREX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 64.7 Max: 227.2
Current: 86.8
0
227.2
3-Year EBITDA Growth Rate -52.10
OREX's 3-Year EBITDA Growth Rate is ranked lower than
92% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. OREX: -52.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OREX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.1  Med: -26.7 Max: -8
Current: -52.1
-52.1
-8
3-Year EPS without NRI Growth Rate -40.60
OREX's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OREX: -40.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OREX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: -24.45 Max: -8.7
Current: -40.6
-55.4
-8.7
GuruFocus has detected 8 Warning Signs with Orexigen Therapeutics Inc $OREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OREX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OREX Guru Trades in Q2 2016

Seth Klarman 22,268,399 sh (unchged)
Jim Simons 549,500 sh (-76.92%)
Paul Tudor Jones 12,073 sh (-84.21%)
» More
Q3 2016

OREX Guru Trades in Q3 2016

Seth Klarman 2,226,839 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2016

OREX Guru Trades in Q4 2016

Seth Klarman 2,226,839 sh (unchged)
» More
Q1 2017

OREX Guru Trades in Q1 2017

Seth Klarman 2,226,839 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:MGWFF, NAS:JNP, OTCPK:MGCLF, NAS:SCYX, NAS:PTX, OTCPK:NRIFF, NAS:EVOK, OTCPK:MRPHF, NAS:BPTH, OTCPK:SENZ, NAS:FCSC, OTCPK:STNY, OTCPK:PTLF, OTCPK:ITHUF, OTCPK:IMLFF, NAS:SNOA, OTCPK:GLDFF, OTCPK:CVSI, NAS:EPIX, OTCPK:KAYS » details
Traded in other countries:JXS1.Germany,
Headquarter Location:USA
Orexigen Therapeutics Inc is a biopharmaceutical company engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product Contrave used for chronic weight management in adults.

Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity.

Ratios

vs
industry
vs
history
PS Ratio 1.00
OREX's PS Ratio is ranked higher than
57% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OREX: 1.00 )
Ranked among companies with meaningful PS Ratio only.
OREX' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 138.4 Max: 4169.57
Current: 1
0.86
4169.57
EV-to-EBIT -2.12
OREX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. OREX: -2.12 )
Ranked among companies with meaningful EV-to-EBIT only.
OREX' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.6  Med: -3.8 Max: 1.8
Current: -2.12
-39.6
1.8
EV-to-EBITDA -2.33
OREX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. OREX: -2.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
OREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.9  Med: -3.8 Max: 1.8
Current: -2.33
-39.9
1.8
Current Ratio 3.21
OREX's Current Ratio is ranked higher than
71% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. OREX: 3.21 )
Ranked among companies with meaningful Current Ratio only.
OREX' s Current Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 3.21
1.99
19.3
Quick Ratio 2.79
OREX's Quick Ratio is ranked higher than
73% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. OREX: 2.79 )
Ranked among companies with meaningful Quick Ratio only.
OREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.99  Med: 6.19 Max: 19.3
Current: 2.79
1.99
19.3
Days Inventory 485.47
OREX's Days Inventory is ranked lower than
99% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. OREX: 485.47 )
Ranked among companies with meaningful Days Inventory only.
OREX' s Days Inventory Range Over the Past 10 Years
Min: 485.47  Med: 776 Max: 776
Current: 485.47
485.47
776
Days Sales Outstanding 47.91
OREX's Days Sales Outstanding is ranked higher than
94% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. OREX: 47.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
OREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.2  Med: 14.42 Max: 101.89
Current: 47.91
8.2
101.89
Days Payable 402.52
OREX's Days Payable is ranked higher than
99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. OREX: 402.52 )
Ranked among companies with meaningful Days Payable only.
OREX' s Days Payable Range Over the Past 10 Years
Min: 402.52  Med: 694.39 Max: 694.39
Current: 402.52
402.52
694.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.70
OREX's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. OREX: -11.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OREX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.3  Med: -23.85 Max: -11.7
Current: -11.7
-178.3
-11.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.01
OREX's Price-to-Median-PS-Value is ranked higher than
100% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. OREX: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OREX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.01 Max: 30.97
Current: 0.01
0.01
30.97
Earnings Yield (Greenblatt) % -47.17
OREX's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. OREX: -47.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47.17  Med: 100.15 Max: 1518
Current: -47.17
-47.17
1518

More Statistics

Revenue (TTM) (Mil) $47.82
EPS (TTM) $ -6.97
Beta2.90
Short Percentage of Float29.48%
52-Week Range $1.65 - 6.49
Shares Outstanding (Mil)15.23

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 86 152
EPS ($) -8.55 -5.14
EPS without NRI ($) -8.55 -5.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Orexigen Announces Activities at European Congress on Obesity 2017 May 16 2017 
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 May 09 2017 
Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcar May 02 2017 
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA May 02 2017 
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on Apr 25 2017 
Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada Apr 25 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Po Apr 05 2017 
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 

More From Other Websites
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio May 24 2017
The 3 Best Obesity-Drug Stocks to Buy in 2017 May 19 2017
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth May 17 2017
Orexigen Announces Activities at European Congress on Obesity 2017 May 16 2017
Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT May 10 2017
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y May 10 2017
Orexigen reports 1Q loss May 09 2017
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 May 09 2017
Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call May 09 2017
Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch... May 02 2017
ETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017 May 02 2017
Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of... May 02 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA... May 02 2017
Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics Apr 28 2017
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on... Apr 25 2017
Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada Apr 25 2017
ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017 Apr 17 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for... Apr 05 2017
Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017 Mar 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)